Evidence map›Paper›PMID 35589156›Full record

ArticleBMJ global health2022

Powers, engagements and resultant influences over the design and implementation of medicine pricing policies in Ghana.

Augustina Koduah, Leonard Baatiema, Irene A Kretchy, Irene Akua Agyepong, Anthony Danso-Appiah, Anna Cronin de Chavez, Timothy Ensor, Tolib Mirzoev

Abstract read
In one paragraph

Article in BMJ global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Augustina KoduahPharmacy Practice and Clinical Pharmacy, University of Ghana School of Pharmacy, Legon, Accra, Ghana akoduah@ug.edu.gh.
Leonard BaatiemaHealth Policy, Planning & Management, University of Ghana School of Public Health, Legon, Accra, Ghana.
Irene A KretchyPharmacy Practice and Clinical Pharmacy, University of Ghana School of Pharmacy, Legon, Accra, Ghana.ORCID 0000-0001-6811-5937
Irene Akua AgyepongDodowa Health Research Centre, Ghana Health Service, Accra, Greater Accra, Ghana.
Anthony Danso-AppiahEpidemiology and Disease Control, University of Ghana School of Public Health, Legon, Accra, Ghana.
Anna Cronin de ChavezGlobal Health and Development, London School of Hygiene & Tropical Medicine, London, London, UK.
Timothy EnsorNuffield Centre for International Health and Development, University of Leeds, Leeds, UK.ORCID 0000-0003-0279-9576
Tolib MirzoevGlobal Health and Development, London School of Hygiene & Tropical Medicine, London, London, UK.ORCID 0000-0003-2959-9187

Funding

Department of Health
6 · The paper itself

Abstract

introductionUniversal availability and affordability of essential medicines are determined by effective design and implementation of relevant policies, typically involving multiple stakeholders. This paper examined stakeholder engagements, powers and resultant influences over design and implementation of four medicines pricing policies in Ghana: Health Commodity Supply Chain Master Plan, framework contracting for high demand medicines, Value Added Tax (VAT) exemptions for selected essential medicines, and ring-fencing medicines for local manufacturing.

methodsData were collected using reviews of policy documentation (n=16), consultative meetings with key policy actors (n=5) and in-depth interviews (n=29) with purposefully identified national-level policymakers, public and private health professionals including members of the National Medicine Pricing Committee, pharmaceutical wholesalers and importers. Data were analysed using thematic framework.

resultsA total of 46 stakeholders were identified, including representatives from the Ministry of Health, other government agencies, development partners, pharmaceutical industry and professional bodies. The Ministry of Health coordinated policy processes, utilising its bureaucratic mandate and exerted high influences over each policy. Most stakeholders were highly engaged in policy processes. Whereas some led or coproduced the policies in the design stage and participated in policy implementation, others were consulted for their inputs, views and opinions. Stakeholder powers reflected their expertise, bureaucratic mandates and through participation in national level consultation meetings, influences policy contents and implementation. A wider range of stakeholders were involved in the VAT exemption policies, reflecting their multisectoral nature. A minority of stakeholders, such as service providers were not engaged despite their interest in medicines pricing, and consequently did not influence policies.

conclusionsStakeholder powers were central to their engagements in, and resultant influences over medicine pricing policy processes. Effective leadership is important for inclusive and participatory policymaking, and one should be cognisant of the nature of policy issues and approaches to policy design and implementation.

Indexed as

Drugs, EssentialPolicy MakingCosts and Cost AnalysisGhanaHumansPolicyDrugs, EssentialHealth policyHealth systems

Identifiers

PMID35589156
PMCPMC9121428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.